FY2027 Earnings Estimate for Neogen Issued By Zacks Research

Neogen Co. (NASDAQ:NEOG) – Research analysts at Zacks Research cut their FY2027 EPS estimates for shares of Neogen in a note issued to investors on Monday, March 3rd. Zacks Research analyst R. Department now anticipates that the company will earn $0.56 per share for the year, down from their previous forecast of $0.57. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings data on Friday, January 10th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.12. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The firm had revenue of $231.30 million during the quarter, compared to the consensus estimate of $227.16 million. During the same period in the prior year, the firm posted $0.11 earnings per share. The company’s quarterly revenue was up .7% compared to the same quarter last year.

NEOG has been the subject of several other research reports. Piper Sandler reissued a “neutral” rating and set a $13.00 price objective (down previously from $16.50) on shares of Neogen in a research report on Tuesday, January 21st. Guggenheim began coverage on shares of Neogen in a research report on Thursday, December 19th. They set a “buy” rating and a $15.00 price target for the company.

Neogen Trading Up 2.0 %

Shares of NEOG opened at $9.60 on Wednesday. Neogen has a 1-year low of $9.01 and a 1-year high of $18.58. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -4.38 and a beta of 1.23. The firm’s 50-day moving average price is $11.24 and its 200-day moving average price is $13.62. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33.

Insider Activity at Neogen

In other Neogen news, CFO David H. Naemura bought 14,800 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were acquired at an average cost of $11.11 per share, for a total transaction of $164,428.00. Following the purchase, the chief financial officer now owns 61,434 shares in the company, valued at approximately $682,531.74. This trade represents a 31.74 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John Edward Adent purchased 23,035 shares of the stock in a transaction dated Thursday, January 16th. The shares were acquired at an average cost of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the acquisition, the chief executive officer now owns 269,164 shares of the company’s stock, valued at approximately $2,968,878.92. This represents a 9.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.13% of the stock is currently owned by insiders.

Institutional Trading of Neogen

Large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC lifted its position in Neogen by 142.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock valued at $33,000 after purchasing an additional 1,165 shares during the period. Harbour Investments Inc. purchased a new stake in Neogen during the 4th quarter valued at $27,000. Blue Trust Inc. boosted its stake in shares of Neogen by 196.7% in the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock worth $41,000 after buying an additional 2,233 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Neogen in the fourth quarter worth $43,000. Finally, Neo Ivy Capital Management purchased a new stake in Neogen during the third quarter valued at $66,000. 96.73% of the stock is currently owned by institutional investors.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.